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Analysis o f eicosanoids released from activated macrophages (94 pp.)
Director: George L. Card
Macrophages are a major source o f the eicosanoid derivatives o f arachidonlc acid, 
which mediate a number o f reactions that have important biological functions. In 
this study, we developed a C18 minicolumn procedure for rapidly separating 
eicosanoid mixtures into prostaglandin, leukotriene, and arachidonic acid fractions.
The procedure was then used to quantify eicosanoids released from macrophages (both 
human THP-1 cells and mouse peritoneal exudate cells) activated with different 
bacterial amphiphiles (lipopolysaccharide (LPS), lipoteichoic acid (LTA), and 
monophosphoryl lipid A), ceramide, and phorbol myristate acetate (PMA). 
Arachidonic acid was the main product in eicosanoid mixtures released from both cell 
lines. The prostaglandin pathway was activated in mouse PEC, but not in human 
THP-1 cells. There were marked differences in the relatgive potency o f different 
amphiphile preparations for the activation o f both cell types. Pretreatment o f THP-1 
cells with 7-interferon was not required for the activation of arachidonic acid 
metabolism in the human THP-1 cell line. Treatment with R595 LPS desensitized 
mouse PEC to subsequent challenge with R595 LPS, but not with either C2-ceramide 
or PM A. HPLC analysis confirmed that arachidonic acid was the main product 
released from activated THP-1 cells and suggested that the eicosanoid mixtures 
released from acitivated cells contained products other than prostaglandins, 
leukotrienes, and arachidonic acid.
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Chapter I 
Introduction
Activated macrophages play a critical role in host 
defense against tumors and microbes, in the development of 
an inflammatory response, in homeostasis and in diseases 
such as atherogenesis, and carcinogenesis. Macrophages 
possess numerous physiologic properties that may be 
modulated during activation. These include alterations in 
intracellular constituents, plasma membrane components, and 
secretion of both protein and lipid mediators (1).
As shown in Fig 1, a variety of metabolic activities 
have been described in activated macrophages. The metabolic 
activities which are commonly used to measure macrophage 
activation include the respiratory burst, secretion of 
proteins and glycoprotein mediators, release of tumor 
necrosis factor(TNF) and other cytokines, display of altered 
surface properties,and the release of arachidonic acid 
metabolites (eicosanoids)(4).
Arachidonic acid is an essential fatty acid which is 
incorporated into membrane phospholipids. The products of 
arachidonic acid metabolism (eicosanoids) mediate a number 
of reactions that have various important biological effects. 
It has also been suggested that the release of other 
mediators (e.g. cytokines) may be dependent on the 
activation of arachidonic acid metabolism. Macrophages are a 
major source of the eicosanoids and, by consideration of 
their importance in host defense, it is clear that their
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release constitutes an important aspect of macrophage 
function.
The activity of macrophages is regulated by 
extracellular signals which can either enhance or diminish 
the ability of macrophages to carry out a certain function. 
Bacterial amphiphiles, including lipopolysaccharides, 
lipoteichoic acids, monophosphoryl lipid A, etc., are 
substances which can enhance the immune response by causing 
sensitive cells, such as macrophages, neutrophils and 
lymphocytes, to release a variety of mediators (4). These 
mediators act as messengers which have many significant 
biological functions, including inflammation(interleukins, 
eicosanoids), tumor destruction (tumor necrosis factor), 
lymphocyte activation (interleukins). This study was focused 
on, the release of eicosanoids (arachidonic acid metabolites) 
by the macrophages (murine and human THP-1) activated with 
different bacterial amphiphiles.
ARACHIDONIC ACID
Eicosanoids are derivatives of arachidonic acid, a C20 
polyunsaturated fatty acid (5-cis-, 8-cis-, 11-cis-, 14-cis- 
eicosatetraenoic acid) (4) (Fig. 2). After activation of 
phospholipase A2, arachidonic acid is released from membrane 
phospholipid, and is then converted to different eicosanoid 
products. There are three major classes of eicosanoids which 
are produced by three major eicosanoid biosynthetic 
pathways: the cyclooxygenase pathway (prostaglandins), the
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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Fig. 2: Structura of a arachidonic acid
5'-lipoxygenase pathways (leukotrienes), and the 12'- and 
15'-lipoxygenase pathway (lipoxins).
The synthesis of the prostaglandin family begins with 
the enzyme cyclooxygenase. Phospholipase A2, which liberates 
arachidonic acid from the phospholipids in cell membranes, 
is the rate-limiting step in eicosanoids synthesis (Fig.3,
4) .
LEUKOTRIENES
The leukotrienes (LTs) are a family of biologically 
active lipids derived from arachidonic acid by the action of 
a 5'-lipoxygenase (26) , They are produced from 
polymorphonuclear cells, neutrophils, eosinophils, 
monocytes, lymphocytes, macrophages, and mast cells (16). 
This family includes the dihydroxyeicosanoid LTB4, a potent 
chemotactic agent, and the peptidolipid leukotrienes LTC4, 
LTD4 and LTE4, which are responsible for the potent smooth 
muscle contractile effect of slow-reacting substance of
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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anaphylaxis (SRS-A)(26). Leukotrienes C4 and D4 have been 
shown to be potent myotropic agents, while Leukotriene E4 is 
somewhat less potent. These and other products of the 
lipoxygenase-pathway have been implicated in the pathology 
of asthma and other hypersensitivity reactions (6). In 
addition, the eukotrienes have potent effects on white cell 
function, (including a variety of phagocytic cells, as well 
as lymphocytes), bronchial tone, and several other 
biological target systems (21).
Because of so many important biological functions and 
profound biochemical effects, this family has been the 
subject of intense interest and there has been considerable 
recent interest in quantifying these compounds in biological 
samples.
PROSTAGLANDINS
Prostaglandins are cyclopentanoic acids derived from 
arachidonic acid which exert hormone-like effects in many 
physiological processes. The primary prostaglandins are 
divided into three types based on the functionality in the 
cyclopentane ring - E type (p-hydroxy-ketones), F type (1,3-
diols), and A type (a,p-unsaturated ketones). The natural 
prostaglandins are also grouped into the mono-, bis-, or 
trisunsaturated classes, according to the number of carbon- 
carbon double bonds in the parent E-type prostaglandin. All 
of the prostaglandins have in common the prostanoic acid
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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skeleton, and typical prostaglandins, like PGE2, have four 
oxygen-functionalized carbon atoms.
The biosynthesis of prostaglandins is initiated by an 
enzyme associated with the endoplasmic reticulum, called 
prostaglandin endoperoxide synthase. The enzyme catalyzes 
simultaneous oxidation and cyclization of arachidonic acid. 
The enzyme has two distinct activities, cyclooxygenase and 
peroxidase(Fig.5).
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Prostaglandins are released from many types of tissue 
in response to injury such as anaphylactic shock, mechanical 
trauma, and inflammation. Pharmacological properties of 
prostaglandins include vasodilatation, increased vascular 
permeability, and leukocytic emigration (10). Prostaglandins 
cause either vasoconstriction or vasodilatation, depending 
on the type of prostaglandin, the type of vascular bed and 
the animal species. Prostaglandins of the A and E series, in 
most vascular beds, induce vasodilatation of both arterioles 
and venules. In man, intravenous prostaglandins cause 
headache and also pain along the veins into which they are 
infused. When administered intradermally or intramuscularly 
in concentrations much higher than those expected to occur 
in inflammation, PGEl causes a long-lasting overt pain. With 
PGF2a, there is an initial brief effect followed by a 
delayed gradual increase. In addition, PGEl can enhance the 
granuloma formation by cotton pellets and increase collagen 
synthesis in chick embryo tibiae. It is also the most 
powerful pyretic agent known, when injected either into 
cerebral ventricles or directly into the anterior 
hypothalmus (10).
Prostaglandins are likely to be important in bone 
metabolism because they are potent multifunctional 
regulators of both formation and resorption. They are 
produced in abundance by bone cells, and by the cells 
adjacent to the bone in the marrow and the periosteal 
tissues. Moreover, prostaglandins probably mediate the
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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effects of mechanical forces on the skeleton. Thus they are 
likely to play a critical role in skeletal physiology and in
the pathologic responses of bone. Recent studies have
confirmed that prostaglandins, particularly PGE2, are potent
stimulators of resorption that act by increasing both the
replication and differentiation of osteoclast precursors. 
Prostaglandins have biphasic effects on bone formation. An 
inhibitory effect on collagen synthesis can be demonstrated 
in cell and organ culture and appears to be transcriptional, 
acting through a PGF receptor that activates protein kinase 
C (25). Several recent studies have shown that the lung is 
one of the major sites of prostaglandin synthesis and 
inactivation. A variety of physiological and pathological 
stimuli including hypoxia, anaphylaxis and hyperinflation 
cause the release of prostaglandins from lung. Thus, it has 
been suggested that there is a relationship between the 
ability of the lung to handle prostaglandin synthesis, 
release and metabolism, and pulmonic diseases. In contrast 
to the peptido-leukotrienes, inhaled prostaglandin E2 
attenuates smooth muscle constriction in airway passages 
(23) .
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BACTERIAL AMPHIPHILES
The bacterial amphiphiles which will be used in this 
study include: lipopolysaccharide ( R-form LPS and S-form 
LPS), monophosphoryl lipid A (MLA) and lipoteichoic acids 
(LTA) from different gram-positive bacteria.
LIPOPOLYSACCHARIDES
Lipopolysaccharide (LPS) is the endotoxin which is 
localized on the surface of bacterial cells, and, together 
with phospholipids and proteins, forms the outer membrane of 
Gram-negative bacteria (5). It can produce adverse reactions 
including circulatory and metabolic failures and often 
lethal shock in animals. These effects have been attributed 
largely to the release of several chemical mediators such as 
interleukins, TNF, and eicosanoids from macrophages. It is 
well known that LPS is able to activate the complement 
cascade and prime polymorphonuclear leukocytes or monocytes- 
macrophages to release these various mediators. The in vitro 
culture of polymorphonuclear leukocytes or peritoneal 
macrophages (PM) with LPS promotes an enhanced respiratory 
burst and release of eicosanoids, events considered 
important in the defense against bacterial infection as well 
as in the progress of tissue damage (31) . The influence of 
endotoxin on the biosynthetic processes of eicosanoids 
remains unclear (8).
LPS is composed of three distinct structural parts:
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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Fig. 6: Structure of lipopolysaccharide
and a hydrophobic component designated lipid A (29) {Fig.
6) . Thereis considerable variation in the amounts of 
polysaccharide in LPS so that some LPS consists 
predominantly of lipid A and is called R-form LPS, whereas 
others have abundant polysaccharide (the 0-side chain) and 
is called S-form LPS. Although the lipid A part of LPS is 
responsible for the endotoxic activities, the polysaccharide 
moiety influences the elimination kinetics, mediates 
specific LPS binding with macrophages and lymphocytes, and 
is essential for activation of the alternate pathway of the 
complement system (8). Since R-form and S-form LPS differ in 
their relative contents of polysaccharide, it is possible 
that they have differential effects on the release of 
chemical mediators and subsequent pathophysiological 
consequences.
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MONOPHOSPHORYL LIPID A
Monophosphoryl lipid A (MLA) is an attenuated 
derivative of LPS that lacks many of the endotoxic 
properties of the parent molecule and yet retains potent 
adjuvant and immunostimulating activities (Fig. 7) . MLA, 
marketed as MPL immunostimulant, has been tested in several 
clinical trials involving a variety of indications, 
formulations, and routes of administration. Many 
studies have shown that MLA is safe in humans at doses that 
are active with respect to a number of immunological 
markers, including induction of cytokines, activation of 
cytotoxic T cells, and protection against a subsequent 
endotoxin challenge (22). Other evidence has shown some 
relationship between MLA and several mediators: MLA induced 
rapid accumulation of interferon-gamma (IFN-y) in mice.
Pig. 7: Structure of
monopho sphory1 
lipid A (MLA)
HO
HO
NH
HO HO
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Tumor necrosis factor-alpha (TNF-a) appeared to be a 
cofactor for IFN-y induction by MLA. With low dose of MLA (< 
5 micrograms), IFN-y induction was dependent upon exogenous 
TNF-a administered either in advance of or with MLA (13).
The monophosphoryl lipid A homologs derived from 
Salmonella minnesota strain R595 have been characterized by 
the combination of FAB-MS (Fast atom bombardment and mass 
spectrometry) and 2D nuclear magnetic resonance spectroscopy 
which included a detailed evaluation of the hepta-, hexa-, 
and pentaacyl MLA (5). This study was interested in 
determining the effects of this partial structure of the 
lipid A moiety of gram-negative lipopolysaccharide, 
monophosphoryl lipid A, on eicosanoid metabolism in 
macrophages.
LIPOTEICHOIC ACID
Lipoteichoic acid (LTA) is a different type of 
amphiphile which is produced by Gram-positive bacteria (11) 
(Fig. 8) . Most LTAs which have been characterized consist of 
a 1,3, linked polyglycerophosphate moiety in a 
phosphodiester linkage to a membrane hydrophobic 
glyceroglycolipid which is anchored at the outer surface of 
the cytoplasmic membrane, with the glycerophosphate chain 
extending into the environment (4). This glyceroglycolipid 
anchor is usually composed of a disaccharide unit linked to 
a diacylglycerol. The length of the polyglycerophosphate
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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Chain varies from 16 to 40 glycerophosphate units, depending 
on the bacterial species (11,33).
HC—0—00—A
Fig. 8: structure of lipoteichoic acid (Staphylococcus aureus)
' 1
The number of group substitutions in the glycerol residues 
also varies among bacterial species. Bacterial LTAs can be 
divided.into four groups based on the chain substitution: 
group A lacks substituents; group B carries only D-alanine 
substituents; group C carries only glycosyl substituents; 
and group D carries both of these substituents (4).
It has been well known that the inflammatory components 
implicated in gram-positive bacteremia are cell wall 
components, toxins, and enzymes. The role of LTA in gram- 
positive bacterium inflammation has not been well 
documented. Some recent research reported that although it 
was relatively non-toxic, lipoteichoic acids could activate 
arachidonic acid metabolism and eicosanoid release from
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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macrophages (17). There is some evidence to show that there 
are humoral and cellular factors that recognized both LPS 
and LTA, and LTA had some immunological and biological 
properties in common with LPS (2,14).
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OBJECTIVES
The major objective of this study was to compare the 
relative amounts of leukotrienes, prostaglandins, and 
arachidonic acid released from macrophages activated with 
different bacterial amphiphiles, including ipopolysaccharide 
(S-form LPS and R-form LPS) and monophosphoryl lipid A (MLA) 
from Gram-negative bacteria, lipoteichoic acid (LTA) from 
Gram-positive bacteria, and phorbol myristic acetate (PMA).
SPECIFIC AIMS
(1) . An analytical strategy was developed for the rapid
extraction, separation, and quantification of the 
relative amount of leukotriene, prostaglandin and 
arachidonic acid released from activated macrophages.
Procedures currently available for eicosanoid 
analysis are expensive (e.g. EIA, RIA) and/or very time 
consuming (e.g. HPLC). Although these have been useful 
for some clinical studies and other experiments 
involving a limited number of samples, they are not 
suitable for the analysis of a large number of samples.
(2). This procedure was used for an analysis of the relative 
amount of prostaglandin, leukotriene, and arachidonic 
acid released from macrophages treated with different 
bacterial amphiphiles.
The analytical strategy developed in Specific 
Aim#l would allow the screening of a large number of 
samples. The working assumption is that substances
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which activate cells to produce markedly different 
mixtures of prostaglandins and leukotrienes will have 
different activities in whole animals.
(3) . Selected amphiphiles (based on the results
obtained in Specific Aim #2) were used to study the 
relative kinetics of prostaglandin and leukotriene 
release from activated macrophages.
Some studies suggest that the accumulation of one 
eicosanoid (e.g. PG-E2) may cause a down-régulâtion of 
the synthesis of other eicosanoids.
(4). Samples which showed significant differences of 
the relative amounts of leukotriene and prostaglandin 
were selected for complete analysis by HPLC and EIA 
assay. These procedures provide the quantitative 
analysis of each of the major prostaglandins and 
leukotrienes as well as arachidonic acid and other 
derivatives. Likewise, samples from the kinetic 
experiments which showed significant changes of 
eicosanoid families over time were analyzed with HPLC 
and EIA assay.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
19
Chapter II 
Materials and Methods
Materials
Octadecyl (C18) minicoluitms were purchased from 
Amersham International (Amersham Place, Buckinghamshire, 
England). Labelled fatty acid and eicosanoids were purchased 
from American Radiolabeled Chemicals Inc (St.Louis, MO). 
Unlabeled lipids, Cellgro RPMI 1640 medium, and fetal bovine 
serum (FES) were obtained from Sigma Chemicals (St.Louis,
MO). Six to ten week-old ICR mice were obtained from Jackson 
laboratory. THP-1 cells, LPS preparations, and vitamin D3
(a-1, 25 dihydro-xyvitamin D) were provided by Ribi 
ImmunoChem Research Institute (Hamilton,MT). LTA 
preparations were from Sigma Chemicals (St. Louis, MO), 
and Ecolume fluor was obtained from ICN Biochemicals 
(Irvine, CA) . Prostaglandin E2 and Leukotriene C4 Enzyme 
Immunoassay Kits were obtained from Cayman Chemical Company 
(Ann Arbor, MI).
Fractionation of eicosanoids on C18 minicolumns
Initial studies were focused on the development of one- 
step column-centrifugation procedures for the rapid 
separation of leukotrienes, prostaglandins and arachidonic 
acid. The reverse-phase C18 bonded silica gel has been 
proven to be very effective for extraction of prostaglandins
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and leukotrienes from biological fluids (27), Known mixtures 
of prostaglandin E2 (PGE2), leukotriene D4 (LTD4) and 
arachidonic acid (AA) containing tritium-labelled lipid were 
used to evaluate the separation procedures. Three mixtures 
of known lipids were used; each contained a mixture of 
unlabelled PGE2 (280 pmole), LTD4 (200 pmole), and 
arachidonic acid (1000 pmole) plus one labelled lipid. 
Mixture 1 contained the unlabelled lipid mixture plus Ĥ- 
PGEl (0.1 (iCi), mixture 2 contained the unlabelled lipid 
mixture plus ^H-LTD4 (0.01 nCi)/ and mixture 3 contained the 
unlabelled lipid mixture plus ^H-arachidonic acid (0.15 
|iCi) .
Solvent systems and elution schemes evaluated in this 
study were selected from solvent systems which have been 
used in HPLC and TLC (thin layer chromatography) procedures 
for separation of these lipids (28,30). The following 
solvents were selected for the final elution scheme: solvent 
A (A) , acetonitrile-methanol-ddH20-acetic acid-EDTA 
(1280:800:1916:4:2 grams); solvent B (B), solvent A-methanol 
(50:50); solvent C (C), solvent A-ddHaO (75:25); solvent D 
(D) , solvent A-methanol (75:25); and methanol. Samples were 
applied to the C18 minicolumns in water. Prostaglandins were 
eluted by successively pushing 1 ml each of solvents C, A, 
and D through the minicolumn with a 1 ml syringe. 
Leukotrienes were then eluted with solvent B, and finally 
arachidonic acid was eluted with methanol. Labelled lipid in
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each fraction was counted in a Beckman LS7500 scintillation 
counter.
Macrophage Cultures
Two types of macrophage cultures were used in this 
study: mouse peritoneal exudate cells (mouse PEC) and human 
THP-1 monocytic cells. These two cell lines have been well 
characterized as excellent models for the study of murine 
and human macrophages, respectively.
Mouse Peritoneal Exudate Cells
Mice were killed with CO2 and PECs were recovered by 
injecting 10 ml of RPMI medium containing 20 )ig/ml of 
gentamicin into the peritoneal cavity. Peritoneal fluids 
were removed, transferred to a centrifuge tube, and 
centrifuged at 1000 rpm for 10 minutes. The cells were then 
resuspended in 10 ml of RPMI medium, counted using a 
hemacytometer, and the cell density was adjusted to 2 - 2.5 
X 10® cells/ml. The cell suspension was added (1.0 ml/well) 
to a 24 well flat-bottom plate. Cells were incubated at 37°C 
in a chamber with 5% CO2 for 2 hours to allow macrophages to 
adhere. Non-adherent cells were then removed and fresh 
medium was added.
Human THP-1 Cells
Human THP-1 cells were grown in RPMI medium containing
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10% FBS serum in 75 cm̂  sterile tissue culture flasks at 
37°C in 5% CO2 . The cell density was adjusted to 1.5 - 2.5 x 
10^ cells/ml.
Bacterial Amphiphiles
Bacterial amphiphiles which were used in this study 
included 1ipopolysaccharide (LPS) and lipoteichoic acid 
(LTA) preparations which have been shown to activate total 
arachidonic acid metabolism (4). LPS preparations included 
smooth LPS from Salmonella abortus (S-LPS), rough LPS from 
Salmonella minnesota R595 (R-LPS), diphosphoryl lipid A 
(DPL) and monophosphoryl lipid A (MLA) obtained from R-595 
LPS, and deacylated LPS preparations. LTA preparations 
included LTA from Bacillus subtilis, Staphylococcus aureus, 
Streptococcus pyogenes, and S. faecalis.
Labeling Procedure
[̂ H] arachidonic acid was used to metabolically label 
the eicosanoids. Adherent mouose peritoneal exudate cells on
the 24-well plate were washed with fresh medium, and then 1
ml of medium containing [^H]-arachidonic acid (0.5 jiCi/well) 
was added to each well. Cells were then incubated overnight 
at 37°C in 5% CO2 .
Human THP-1 cells were pretreated with vitamin D3 (1
pM/ml) overnight in a 75 cm̂  sterile tissue culture flask at
37°c in 5% CÔ . After overnight pretreatment, cells were
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harvested, counted, and transferred to a centrifuge tube, 
centrifuged at 1000 rpm for 10 minutes. Then the cells were 
resuspended in 24 ml of RPMI medium with 10% FBS serum
containing -arachidonic acid (0.5 |iCi/ml). The cell 
suspension was then added (1.0 ml/well) to a 24 well flat- 
bottom plate, and incubated overnight at 37°c in 5% CO2. At 
the end of the overnight incubation, the unincorporated 
label was removed and the cells were washed three times with 
fresh medium.
Macrophage Challenge
Cells were challenged in medium with serum with an 
amphiphiles, or ceramide, or phorbol myristate acetate 
(PMA) . Cells were incubated at 37°C with 5% CO2 for 
different challenging time period, and/or with different 
concentrations of the bacterial amphiphiles, as indicated.
At the end of the incubation period the medium from each 
well was collected and centrifuged in an Eppendorf 5414 
table top centrifuge to remove any cells. Lipids released 
from cells labeled with [^H]-arachidonic acid was determined 
in 100 (il from each sample collected in scintillation vials 
with 4 mis of Ecolume fluor. The remaining 900 |il from each 
sample was analyzed with the C18 minicolumn separation 
procedure for analysis of the relative amount of 
prostaglandins, leukotrienes and arachidonic acid as 
described above.
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Samples which showed significant differences in the 
relative amounts of leukotrienes and prostaglandins were 
selected for complete analysis by HPLC.
HPLC Analysis
The high-performance liquid chromatograph was performed 
with a 4.6 X 250 mm Silica C18 column, which was attached to 
a PERKIN-ELMER Series 410 LC Pump, a FLO-ONE\Beta Series A- 
100 radioactivity detector, and a PERKIN-ELMER LC-90 UV 
Spectrophotometric detector. The solvent system was a gradi­
ent of solvnet A (acetonitrile:methanol:ddH20:acetic a- 
cid:EDTA = 1280 ; 800 ; 1916: 4 : 2 gram) and methanol eluted at 
the flow rate of 1 ml/min in the following order: 0 min,
100% A; 30 min, 100% A; 31 min, 100% methanol; 51 min, 100% 
methanol; 52 min, 100% A; 67 min, 100% A. Tritium-labelled 
PGEl, LTD4, and arachidonic acid were selected as standards 
which were the representative of different eicosanoid fami­
lies for the radioactivity detector.
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RESULTS
Binding Affinity of Different Eicosanoids on CIS Minicolumns
Initial studies were focused on an analysis of the 
binding affinity of eicosanoids on C18 minicloumns. Samples 
consisted of 280 pmole of unlabelled PGE2, 1100 pmole of 
unlabelled arachidonic acid, and 200 pmole of unlabelled
leukotriene D4 plus either 0.1 p,Ci of ^H-PGEl or 0.01 |iCi of 
^H-LTD4 in 1 ml of RPMI with 10% FBS culture medium. RPMI 
medium with 10% FBS serum, which was used for culturing both 
mouse and human THP-1 macrophages, was added to make the 
final vaule of each sample to be 1 ml. A 50 p.1 aliquot from 
each sample was removed to determine total CPM loaded on the 
columns. The remaining portion of each sample was loaded 
onto each of two Cl8 minicolumns. After each sample passed
through the column, a 50 [xl aliquot of the eluate was 
counted to determine the amount of labelled eicosanoid which 
was not bound on the column. Over 96% of ^H-PGEl and 88% of 
^H-LTD4 were bound to the Cl8 minicolumns. The amount bound 
was not significantly increased by passing the effluent
through the columns a second time.
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Columns
The binding of PGEl and LTD4 to silicic acid was 
measured in different solvents in order to select the most 
appropriate solvent for loading and eluting samples. The 
following solvents were selected for this study; 99% 
ethanol, e t h a n o l (4:1), ethanol :H2O (2:1), ethanol:H20 
(1:4), hexane, toluene, and methanol. Samples, 100 |il each, 
consisted of mixed unlabelled eicosanoids as described 
above, were labelled with either 0.1 p.Ci [̂ H] -PGEl or 0.01 
|iCi [^H]-LTD4. 400 |j,l of each solvent listed above was added 
to make the final vaule of each sample to be 0.5 ml. A 10 pi 
aliquot from each sample was removed to determine total CPM 
loaded. Silicic acid was loaded into 1.5 ml centrifuge 
tubes, 40 mg each tube. Samples were then loaded into the 
tubes and mixed with silicic acid. After 15 mintues, all 
tubes were centrifuged at 14,000 rpm for 30 seconds, and a 
10 pi aliquot of the supernatant of each sample was removed 
to determine the amount of labelled eicosanoids which did 
not bind to the silicic acid in the centrifuge tubes. Our 
results indicated that among the different solvents listed 
above, eicosanoids had high binding affinity with silicic 
acid in either hexane or toluene. Over 98.7% of ^H-PGEl and 
98.3% of ^H-LTD4 bound with silicic acid in hexane, and over 
98.6% of ^H-PGEl and 98.1% of ^H-LTD4 bound with silicic 
acid in toluene. Based on these results, toluene was
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selected as the first solvent in the elution system.
Separation of Leukotrienes, Prostaglandins, and Arachidonic 
Acid on CIS Minicolumns
Three samples which consisted of the unlabelled 
eicosanoid mixture described above were labelled with [̂ H]- 
PGE2, [^H]-LTD4, or -AA. A 50 f̂l aliquot was taken from 
each sample and counted to determine total CPM loaded on the 
columns. The remaining portion of each sample was loaded 
onto CIS minicolumns, and eluted successively with solvents 
C, A, and D (fraction #1), solvent B (fraction #2), and 
finally methanol (fraction #3). The recovery for [^H]-PGE2, 
[^H]-LTD4, and [^H]-AA was 89%, 54.34% and 96%, respectively 
(Fig. 9).
A sample containing a mixture of labelled PGE2 (36.6% 
of total), LTD4 (15.3% of total), and arachidonic acid 
(48.1% of total) was loaded onto the CIS minicolumn. As 
shown in (Fig. 10), the amount recovered in each fraction 
was almost identical to the expected value.
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Fig. 9: Separation of standard mixture of prostaglandins,
leukotrienes, and arachidonic acid on CIS minicolumn.
The standard mixture of unlabeled eicosanoids consisted of 
280 pmole of PGE2, 1100 pmole of arachidonic acid, and 200 
pmole of leukotriene D4. Mixture #1, 2, and 3 consisted of 
the standard mixture plus labeled ^H-PGEl (0.1 jiCi/sample) 
(solid bar), ^H-LTD4 (0.01 jiCi/sample)(spotted bar), and 
AA (0.12 |iCi/sample) (hatched bar), respectively. The lipid 
was applied to a C18 minicolumn in RPMI medium. Fraction 1 
was eluted with solvent C, A and D, successively, fraction 2 
with solvent B, and fraction 3 with methanol.
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Fig. 10: Fractionation of an eicosanoid mixture on Cl8
minicolumns.
A known mixture consisting of 0.1 fxCi ^H-PGEl, 0.01 p,Ci
LTD4/ and 0.12 jiCi ^H-AA was fractionated on C18 minicolumn 
as described in the legend of Fig. 9. The amount of label 
recovered in each fraction (solid bar) is compared to the 
actual amount of each labeled lipid added to the mixture 
(hatched bar).
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Separation of Leukotrienes, Prostaglandins, and Arachidonic 
Acid on Silicic Acid Columns
Three samples which consisted of the unlabelled 
eicosanoid mixture as described above were labelled with 0.1 
îCi [^H]-PGE1, 0.01 nci [^H]-LTD4, or 0.12 nCi [^H]-AA. A 10 
|i,l aliquot from each sample was removed to determine total 
CPM loaded on the column. Silicic acid was loaded onto 
centrifuge columns, 60 mg each column. Samples were then 
loaded onto each one of three centrifuge columns, and 
sequentially eluted twice with each of the following 
solvents: toluene, solvent A1 (toluene;ethyl 
acetate :methanol=60: 40 : 0), solvent A2 (toluene: ethyl 
acetate : methanol=60: 40:2), solvent A3 (toluene : ethyl 
acetate: methanol= 60:40:20), solvent B1 (acetonitrile: 
methanol: ddH20:acetic acid :EDTA=1280: 800:1916: 4 : 2 grams), 
solvent B2 (solvent Bl:methanol= 50:50), and methanol. As 
shown in Fig 11, the silicic acid column procedure could 
separate LTD4 from both PGEl and arachidonic acid, but it 
was not effective for separation of prostaglandins and 
arachidonic acid. In order to confirm this separation 
result, fraction #3, 4, and 5, which had the highest CPM 
counts from the ^H-PGEl-silicic acid column, were mixed 
together as sample A. And fraction #9 and 10, which had the 
highest CPM counts from ^H-LTD4-silicic acid column, were 
also mixed together as sample B. Sample A and B were then
dried, resuspended in 100 jil of 99% ethanol each, loaded
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onto each of two new silicic acid columns, respectively, and 
eluted as described above. The results, as shown in Fig 12, 
confirmed that ^H-PGEl were eluted with toluene, solvent Al, 
A2 and A3, and ^H-LTD4 were eluted with solvent B1 and B2, 
Based on these findings, we defined the toluene - solvent Al 
” A2 - A3 as the prostaglandin fraction, and Solvent B1 - B2 
- methanol as the leukotriene fraction.
In order to compare the separation effectiveness of the 
silicic acid column procedure and the C18 minicolumn 
procedure, three samples containing a labelled mixture of 
^H-PGEl only, ^H-LTD4/^H-PGE1 = 38/62, or ^H-LTD4 only, were 
loaded onto each of three silicic acid columns and eluted as 
described above. The amount of label recovered in each 
fraction was closer to the applied value for the C18 
minicolumns {Fig. 10) than for the silicic acid columns 
(Fig. 13) .
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
32
3 H -P G E 1 3H-LTD4 3H-AA
I
i
2000
1600
1200
800
400
O
A l A l A 2 A2 A 3 A 3 B1 B1 B2 B 2 M l M2 
F ractions
Fig. 11: Separation of the standard mixture of
prostaglandins, leukotrienes, and arachidonic acid on 
silicic acid columns.
Mixture #1 (solid bar), #2 (hatched bar), and #3 (open bar) 
were prepared as described in Fig. 9. The lipid was applied 
to the silicic acid columns in RPMI medium. Fraction: T
(toluene); Al(toluene : ethyl acetate:methanol=60: 40 : 0); A2 
( toluene:ethyl acetate:methanol=60: 40:2) ; A3(toluene : ethyl 
acetate:methanol=60: 40:20); B1(acetonitrile:methanol:ddHzO 
: acetic acid:EDTA=1280:800:1916:4:2 grams); B2: (B1:methanol= 
50:50); M:methanol.
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Fig. 12: Confirmation of the separation efficiency of
prostaglandins and leukotrienes on silicic acid column.
Fraction #3, 4, and 5 from the ^H-PGEl-silicic acid column 
as shown in Fig. 11 were mixed together as sample 
PGEl", and fraction #9 and 10 from the ^H-LTD4-silicic acid 
column in Fig. 11 were mixed as sample "B:^H-LTD4". Samples
A and B were then dried, resuspended in 100 |il of 99% 
ethanol, loaded onto two new silicic acid columns, and 
eluted as described in the legend of Fig. 11.
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Fig. 13: Fractionation of an eicosanoid mixture on silicic
acid columns.
Three samples# each cotaining the standard unlabeled mixture 
as described in Fig. 9 plus H-PGEl only (Sample #1)# 
LTD4/^H-PGEl=38/62 (Sample #2), and ^H-LTD4 only (Sample 
#3), were fractionated on three silicic acid columns as 
described in the legend of Fig. 11. The amount of label 
recovered in each fraction (solid bar) is compared to the 
actual amount of each labeled lipid added to the mixture 
(hatched bar).
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
3 5
The relative Amount of Label in the Different Eicosanoid 
Fractions Released from LPS Activated THP-1 Cells Was 
Similar Throughout the Activation Period
THP-1 cells (5.25 x 10̂  cells/ml x 20 ml) were 
pretreated with vitamin D3 (1 [iM/ml) and metabolically 
labelled with [̂ H] arachidonic acid (0.5 |iCi/ml) overnight. 
The cells were then challenged with smooth-LPS from S. 
abortus or rough-LPS from S. minnesota (R595) at a 
concentration of 1000 ng/ml. One ml samples were removed at 
0, 15, 30, 60, 90, and 120 minutes after the addition of 
LPS, and then centrifuged. A 100 pi aliquot of the 
supernatant was removed from each sample and counted for 
total label released {Fig. 14]. The remaining portion 
of each sample was subsequently fractionated on C18- 
minicolumns. The major eicosanoid recovered at each time 
point was arachidonic acid. Only trace amounts of label were 
recovered in the prostaglandin or leukotriene fractions in 
the mixture released from S. abortus LPS treated cells.
{Fig. 15). Less than 5% of the total bound lipid was 
recovered in the prostaglandin fraction of the lipid 
released from the cells challenged with R595 LPS, and both 
arachidonic acid (40% to 60%) and leukotrienes (20% to 30%) 
were recovered from C18 minicolumn separation (Fig. 16). In 
addition, between 30% and 40% of the label released from the 
cells did not bind to the Cl8-minicolumns when applied in 
RPMI medium. These products were apparently quite polar.
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Pig. 14: Time course for label released from human THP-1.
cells challenged with S.abortus or S.minnesota (R595) LPS.
Human THP-1 cells (8.7 x 10̂  cells/ml x 40 ml) were 
pretreated with vitamin D3 (1 liM/ml) and metabolically 
labelled with ^H-arachidonic acid (0.5 pCi/ml) overnight. 
The cells were then challenged with either S.abortus LPS or 
S.minnesota LPS at a concentration of 1000 ng/ml in RPMI 
medium with 10% FBS. One ml samples were removed at 0, 15, 
30, 60, 90, and 120 minutes after the addition of LPS, and 
centrifuged. A 100 |al aliquot of each supernatant was 
counted to determine total label released from the cells.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
37
o EZZ3 15 Wmm  3o Kssssa eo ^2% ) @o i i 120
M M M  M M
îI
!
100
80
60
40
20
c m
Unbound PG  LT AA
F raction
Fig. 15: Time course for eicosanoid release from activated
human THP-1 cells challenged with S. abortus LPS.
THP-1 cells were pretreated and challenged as described in 
the legend of Fig. 14. After the 100 ji.1 aliquot from each 
sample was taken to be counted/ the remaining portion of 
each sample was fractionated on CIS minicolumns as described 
in the legend of Fig. 9. Unbound: ^H-labelled polar 
products which did not bind to the CIS minicolumn;
PG:prostaglandin family; LT: leukotriene family; AA: 
arachidonic acid family.
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Fig. 16: Time course for eicosanoid release from activated
human THP-1 cells challenged with S. minnesota LPS.
Human THP-1 cells were pretreated and challenged as 
described in the legend of Fig. 14. After the 100 pi 
aliquot was removed from each sample to be counted, the 
remaining portion of each sample was fractionated on CIS 
minicolumns as described in the legend of Fig. 9. Unbound: 
^H-labelled polar products which did not bind to the C18 
minicolumn; PG: prostaglandin family; LT: leukotriene 
family; AA: arachidonic acid family.
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(R595) Released Both PGEz and LTC,
In order to quantify individual eicosanoids, EIA kits 
were used to analyse the lipids released from human THP-1 
cells activated with S. minnesota LPS.
THP-1 cells (7.4 x 10̂  cells/ml x 20 ml) were 
pretreated with vitamin D3 and metabolically labelled with 
^H-arachidonic acid overnight as described above. S. 
minnesota LPS was then used to challenge the cells at a 
concentration course of 0, 0.1, 1, 10, 100, 1000 ng/ml 
following the same experimental procedure as previous. As 
shown in Fig. 17, S. minnesota LPS activated arachidonic 
acid metabolism in THP-1 cells. The Prostaglandin E2 and 
Leukotriene C4 Enzyme Immunoassay kits were used to analyse 
eicosanoids released from the cells. As shown in Fig. 18, 
both prostaglandin E2 and leukotriene C4 were recovered, and 
the results also showed that more leukotriene C4 was 
released than the amount of prostaglandin E2.
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Fig. 17; CPM released from human THP-1 cells challenged at 
various concentrations with S. minnesota LPS (R595).
Human THP-1 cells (6.9 x 10̂  cells/ml x 20 ml) were 
pretreated and labelled as described in the legend of Fig. 
14. The cells were then challenged with S. minnesota LPS at 
the concentration course of 0, 0.1, 1, 10, 100, 1000 ng/ml 
in RPMI medium with 5% FBS for two hours. One ml samples 
were then collected, centrifuged, and a 100 jil aliquot of 
each supernatant was counted to determine total label 
released from the cells.
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Fig. 18: Enzyme immunoassay analysis of eicosanoids
released from human THP-1 cells challenged with S.mlnnesota 
LPS (R595) at various concentrations.
Human THP-1 cells were pretreated/ labelled, and challenged 
as described in the legend of Fig. 17. A 50 p.1 aliquot of 
each sample was analysed for prostaglandin E2 and for 
leukotriene C4 with the specific EIA kits.
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4 2The Kinetics of Activation of THP-1 Cells with Lipoteichoic Acid were Similar to the Kinetics of Cells Activated with 
LPS
THP-1 cells {7.5 x 10̂  cells/ml x 20 ml) were 
pretreated with vitamin D3 and metabolically labelled with 
[^H]-arachidonic acid overnight as described above. The 
cells were then challenged with LTA at a concentration of 
1000 ng/ml following the same experimental procedure as 
described above. S. faecalis LTA activated arachidonic acid 
metabolism in human THP-1 cells {Fig. 19) . Samples were 
collected at intervals and fractionated on CIS minicolumns. 
Between 20% to 30% of the label released from the cells did 
not bind to the column. The bound label was recovered 
primarily in the arachidonic acid fraction (between 40% 
and 60%) and the leukotriene fraction (between 20% to 25%) 
(Fig. 20) .
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Fig. 19: Time course for label released from human THP-1
cells challenged with S, faecalis LTA.
Human THP-1 cells (7.5 x 10̂  cells/ml x 20 ml) were 
pretreated and labelled as described in the legend of Fig. 
14. The cells were then challenged with S. faecalis LTA at 
a concentration of 1000 ng/ml in RPMI medium with 10% FBS. 
One ml samples were removed at 0, 15, 30, 60, 90, and 120 
minutes after the addition of LTA, and centrifuged. A 100 pi 
aliquot of each supernatant was counted to determine total 
label released from the cells.
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Fig. 20: Time course for eicosanoid release from activated
human THP-1 cells challenged with S. faecalis LTA.
Human THP-1 cells were pretreated and challenged as 
described in the legend of Fig. 19. After the 100 jal 
aliquot was removed from each sample to be counted/ the 
remaining portion of each sample was fractionated on CIS 
minicolumns as described in the legend of Fig. 9. Unbound: 
^H-labelled polar products which did not bind to the CIS 
minicolumn; PG: prostaglandin family; LT; leukotriene 
family; AA: arachidonic acid family.
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The Relative Amount of Label Recovered in Different 
Eicosanoid Fractions was Similar for THP-1 Cells Activated 
with Different LTA preparations
THP-1 cells (3.4 x 10̂  cells/ml x 15 ml) were 
differentiated with vitamin D3 and labelled with Ĥ- 
arachidonic acid as described above. The cells were then 
challenged with LTA from S.pyogenes, B.subtilis, and 
S.aureus in RPMI medium with 5% FBS for two hours. As shown 
in Fig. 21, S.pyogenes, B.subtilis, and S.aureus LTA 
activated arachidonic acid metabolism in THP-1 cells, and 
S.aureus LTA appeared to have the most potent effect for 
this activation. Samples from cells challenged with 1000 
ng/ml of each amphiphile were analyzed on CIS minicolumns. 
The relative amounts of prostaglandins, leukotrienes, and 
arachidonic acid were similar for each of these LTA 
preparations (Fig. 22) and the S.faecalis preparation {Fig. 
20) . About 50% of the total label released from the cells 
was recovered in arachidonic acid fraction, and about 10% of 
the label was recovered in leukotriene fraction. Less than 
2% of the label was found in prostaglandin fraction. Between 
35% and 40% of the label did not bind to the CIS minicolumn.
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Fig. 21: Label released from human THP-1 cells challenged
at various concentrations with S.pyogenes, B.subtilis, and 
S.aureus LTA.
Human THP-1 cells (3.3 x 10̂  cells/ml x 15 ml) were 
pretreated and labelled as described in the legend of Fig. 
14. The cells were then challenged with S.pyogenes,
B.subtilis, and S.aureus LTA at the concentration course of 
0, 0.1, 1, 10, 100, 1000 ng/ml in RPMI medium with 5% FBS 
for two hours. All the samples were then collected, 
centrifuged, and a 100 pi aliquot of each supernatant was 
counted to determine total label released from the cells.
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Fig. 22: Eicosanoids released from activated human THP-1
cells challenged with 1000 ng of LTA from S.pyogenes, 
B.subtilis, or S.aureus.
Human THP-1 cells were pretreated and challenged as 
described in the legend of Fig. 21. After the 100 |xl 
aliquot was removed from each sample to be counted, the 
remaining portion of each sample was fractionated on CIS 
minicolumns as described in the legend of Fig. 9. Unbound: 
^H-labelled polar products which did not bind to the CIS 
minicolumn; PG: prostaglandin family; LT: leukotriene 
family; AA: arachidonic acid family.
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4 8Pretreatment of THP-1 Cells with Human Gamma Interferon did 
not Alter the Pattern of Arachidonic Acid Metabolism
y-IFN pretreatment has a marked influence on the 
response of some cells to LPS. Some macrophage cultures 
require exposure to y-IFN in order to respond to LPS. To 
determine the effect of y-IFN on arachidonic acid metabolism 
in human THP-1 cell line, THP-1 cells {4.5 x 10̂  cells x 30 
ml) were pretreated with human y-IFN at 20 ng/ml during the 
overnight labeling period. Cells without y-IFN pretreatment 
were used as control. Cells were then challenged with R595 
LPS in RPMI medium with 5% FBS for 2 hours. As shown in Fig.
23, arachidonic acid metabolism was activated in both y-IFN 
pretreated and non-pretreated cells, and the activation was 
almost identical in both cell preparations, indicating that 
y-IFN was not required for activating arachidonic acid 
metabolism in human THP-1 cell line.
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Fig. 23: Effect of human y-interferon on arachidonic acid
metabolism in human THP-1 cells.
Human THP-1 cells (4.5 x 10̂  cells/ml x 30 ml) were 
pretreated and labelled as described in the legend of Fig.
14. Half of the cells were pretreated with human y- 
interferon at 20 ng/ml overnight. S.minnesota LPS was then 
used to challenge both y-IFN pretreated (solid line) and 
non-pretreated cells (broken line) in RPMI medium with 5% 
FBS for two hours. One ml samples were then collected, 
centrifuged, and a 100 (il aliquot of each supernatant was 
counted to determine total label released from the cells.
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5 0Mouse Peritoneal Macrophages (PEC) were More Sensitive to PMA than Human THP-1 Macrophages
Some macrophage cultures {e.g. mouse peritoneal 
macrophages) are very sensitive to the phorbol myristate 
acetate (PMA). PMA is an analogue of diglyceride and 
therefore does not require the amphiphile receptor(s) in the 
membrane. To compare the effects of PMA, S. minnesota LPS, 
and S. faecalis LTA on arachidonic acid metabolism in human 
THP-1 monocytic cells and mouse PEC, THP-1 cells were 
distributed into a 12-well flat-bottom plate at a 
concentration of 4.8 x 10̂  cells/well, and mouse PEC were at 
a concentration of 1.9 x 10® cells/well. S. minnesota LPS,
S. faecalis LTA, and PMA were then used to challenge the 
cells at a concentration of 1000 ng/ml in RPMI medium with 
10% FBS. Three wells of the cells were used as controls for 
unchallenged cells in each plate. After four hours 
incubation at 37°C in a chamber with 5% CO2, one ml samples 
were removed from each well, and then centrifuged. A 100 p.1 
aliquot of the supernatant was removed from each sample and 
counted for total label released. The remaining portion of 
each sample was fractionated on C18 minicolumns.
S. minnesota LPS was the most potent activator (2000 ± 
cpm/10^ cells), and PMA had the least effect (1000 ± cpm/10® 
cells) in human THP-1 cells. In contrast to the THP-1 cells, 
PMA had the strongest effect for the activation in mouse PEC 
macrophages (Fig. 24) . The composition of the eicosanoid
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mixture released from PMA treated THP-1 cells was similar to 
LPS and LTA treated cells (Fig. 25) . Mouse PEC cultures 
released more label in the prostaglandin fraction than human 
THP-1 cells (Fig. 26) .
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Fig. 24: Comparison of the effects of S. minnesota LPS,
S. faecalis LTA, and PMA on arachidonic acid metabolism in 
human
THP-1 cells and mouse peritoneal macrophages (PEC).
THP-1 cells (9.6 X 10̂  cells/ml x 40 ml) were pretreated and 
labelled as described in the legend of Fig. 14. Mouse PEC 
were collected (1.9 x 10̂  cells/ml x 12 ml), washed with 
RPMI medium without serum, and metabolically labelled with
^H-arachidonic acid (0.5 pCi/ml) overnight. Both of the 
cell lines were then challenged with S. minnesota LPS, S. 
faecalis LTA, or PMA at a concentration of 1000 ng/ml in 
RPMI medium with 10% FBS for four hours. One ml samples
were then removed, centrifuged, and a 100 pi aliquot was 
removed from each supernatant to be counted for total label 
released from the cells.
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Fig. 25: Eicosanoids released from activated human THP-1
cells challenged with S. minnesota LPS, S. faecalis LTA, or 
PMA.
THP-1 cells were pretreated and challenged as described in 
the legend of Fig. 24. After the 100 pi aliquot was removed 
from each sample to be counted, the remaining portion of 
each sample was fractionated on C18 minicolumns as described 
in the legend of Fig. 9. Unbound; ^H-labelled polar 
products which did not bind to the C18 minicolumn;
PG:prostaglandin family; LT:leukotriene family; AA: 
arachidonic acid family.
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Fig. 26: Eicosanoids released from activated mouse
peritoneal macrophages (PEC) challenged with S. minnesota 
liPS, S. faecalis LTA, or PMA.
Mouse PEC were collected, washed, labelled, and challenged 
as described in the legend of Fig. 24. After the 100 jil 
aliquot was removed from each sample to be counted, the 
remaining portion of each sample was fractionated on CIS 
minicolumns as described in the legend of Fig. 9. Unbound: 
^H-labelled polar products which did not bind to the CIS 
minicolumn; PG: prostaglandin family; LT: leukotriene 
family; AA: arachidonic acid family.
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Comparison of the Effects of C2-ceramide, Sphingomyelinase, and Dihydrocercunide on Arachidonic Acid Metabolism in Mouse 
Peritoneal Macrophages (PEC)
To compare the effects of C2-ceramide, 
sphingomyelinase, and dihydroceramide on arachidonic acid 
metabolism in mouse PEC, mouse PEC were collected (1.1 x 
10®/ml X 26 ml), washed, and labelled overnight as described 
in "Materials and Methods". Following the same experimental 
procedure as described above, C2-ceramide, sphingomyelinase, 
and dihydroceramide were used to challenge the cells in RPMI 
medium with 2.5% FBS at the concentrations of 2.5, 5, 10,
20, 40, 80 pM/ml, 0.03, 0.06, 0.125, 0.25, 0.5, 1 unit/ml, 
and 2.5, 5, 10, 20, 40, 80 pM/ml, respectively. After four 
hours incubation at 37°C in the chamber with 5% COg, all the 
samples were collected, centrifuged, and transferred to 
clean centrifuge tubes. A 100 pi aliquot from each sample 
was removed and counted for total label released. As shown 
in Fig. 21, both C2-ceramide and sphingomyelinase 
activated arachidonic acid metabolism in mouse PEC. 
Dihydroceramide had no apparent effect on this activation.
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Fig. 27: Comparison of the effects of C2-ceramide,
sphingomyelinase/ and dihydroceraimide on arachidonic acid 
metabolism in mouse peritoneal macrophages (PEC).
Mouse PEC were collected (1.1 x 10® cells/ml x 24 ml), 
washed, and labelled as described in the legend of Fig. 24.
The cells were then challenged with C2-ceramide or 
dihydroceramide at 2.5, 5, 10, 20, 40, 80 pM/ml, or with 
sphingomyelinase at 0.03, 0.06, 0.125, 0.25, 0.5, 1 unit/ml 
in RPMI medium with 2.5% FBS for four hours. One ml samples 
were then collected, centrifuged, and a 100 jil aliquot was 
removed from each supernatant to count for total label 
released from the cells.
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Effect of R595 LPS Pretreatment of Macrophage Cultures 
(Mouse PEC) on Subsequent Challenge with S. minnesota LPS, 
Cerconide, and Phorbol Myristic Acetate (PMA)
To understand the nature of desensitization by R595 LPS 
treatment, mouse PEC were collected (2.54 x 10® cells/ml x 
12 ml), washed, and treated with S. minnesota LPS at a 
concentration of 100 ng/ml in RPMI medium with 10% FBS on a 
24-well flat-bottom plate, 1 ml per well. Nine wells of the 
cells were used as control (untreated) samples. After three 
hours incubation at 37°C in the chamber with 5% CO2, the 
medium was removed, and RPMI medium containing Ĥ- 
arachidonic acid was used to label the cells (0.5 |iCi/ml) 
overnight as described before.
After overnight incubation, the medium was removed, and 
the cells were washed three times with RPMI medium without 
serum. Then S. minnesota LPS, ceramide, and PMA were used to 
challenge both LPS treated and control (untreated) cells in 
RPMI medium with 10% FBS at concentrations of 1000 ng/ml, 80 
pM/ml, and 1000 ng/ml, respectively. Three wells of each 
LPS-treated and untreated cells were used as control samples 
for unchallenged cells. After two hours incubation at 37°c 
in the chamber with 5% CO2, one ml samples were removed,
centrifuged, and transferred to clean tubes. A 100 p.1 
aliquot of the supernatant was removed from each sample and 
counted for total label released. The remaining portion of 
each sample was fractionated on CIS minicolumns.
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As shown in Fig. 28, for the untreated cells, 5. / 
minnesota LPS activated arachidonic acid metabolism, and 
ceramide was less effective for the activation. In contrast, 
the pretreated cells showed no response to R595 LPS, but an 
enhanced response to PMA. No apparent change of activation 
was observed for the effect of ceramide between LPS-treated 
and untreated mouse PEC. CIS minicolumn separation showed 
that there was no apparent difference in the composition of 
the eicosanoid mixture released from LPS-treated and 
untreated mouse PEC which were challenged with S. minnesota 
LPS and PMA. ^H-labelled polar products, arachidonic acid, 
leukotrienes, and prostaglandins were all recovered from the 
separation. Apparent difference was observed from the 
separation of samples released from LPS-treated and 
untreated mouse PEC which were challenged with ceramide. All 
^H-labelled polar products, arachidonic acid, leukotrienes, 
and prostaglandins were recovered from the samples released 
from untreated cells. But only ^H-labelled polar products 
and arachidonic acid were recovered from the samples 
released from LPS-treated cells. No label was recovered in 
the leukotriene and prostaglandin fractions (Fig. 29).
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Fig. 28: Effect of R595 LPS pretreatanent of macrophage
cultures (mouse PEC) on subsequent challenge with S. 
minnesota LPS, C2-ceramide, and PMA.
Mouse PEC were collected (2.54 x 10® cells/ml x 6 ml), 
washed, and pretreated with R595 LPS at a concentration of 
100 ng/ml in RPMI medium with 10% FBS for three hours. The 
medium was then removed, and the cells were labelled 
overnight as described in the legend of Fig. 24. The cells 
were then challenged with S. minnesota LPS at 1000 ng/ml,
C2-ceramide at 80 pM/ml, or PMA at 1000 ng/ml respectively 
in RPMI medium with 10% FBS for two hours (hatched bar).
The same amount of untreated mouse PEC were labelled and 
challenged following the same experimental procedure as 
described above (solid bar). After two hours challenging, 
all samples (1 ml each) were removed, centrifuged, and a 100 
|il aliquot from each supernatant was taken to count for 
total label released from the cells.
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Fig. 29: Eicosanoids released from activated mouse
peritoneal macrophages, both R595 LPS pretreated and 
untreated, challenged with S. minnesota LPS, ceramide, or 
PMA..
Mouse PEC were collected, pretreated with R595 LPS,labelled, 
and challenged as described in the legend of Fig. 28. After
the 100 p.1 aliquot from each sample was taken to be counted, 
the remaining portion of both R595 LPS pretreated and 
untreated samples were fractionated on 018 minicolumns as 
described in the legend of Fig. 9. Unbound: ^H-labelled 
polar products which did not bind to the 018 minicolumn;
PG: prostaglandin family; LT: leukotriene family; AA; 
arachidonic acid family.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
6 1
HPLC Analysis
Standard mixture containing unlabelled LTD4 (100 pmole) 
plus ^H-PGEl (0,1 nCi), ^H-LTD4 (0.05 îCi) , and ^H-AA (0.15 
p.Ci) was analysed through HPLC. The HPLC system was 
performed as described in "Materials and Methods", and these 
components were well quantified using the in line 
radioactivity flow detector (Fig. 30) .
Samples released from THP-1 cells challenged with R595 
LPS as described above were analysed with HPLC system, and 
this analysis confirmed the Cl8 minicolumn separation result 
that arachidonic acid was the main product in the eicosanoid 
mixture released from the cells.(Fig. 31) .
Samples released from THP-1 cells challenged with R595 
LPS as described above were fractionated on CIS minicolumns, 
and the prostaglandin, leukotriene, and arachidonic acid 
fractions were then concentrated and analysed with HPLC 
system. Arachidonic acid was recovered as main product in 
the arachidonic acid fraction. The HPLC system lacked the 
sensitivity to detect label in the prostaglandin or 
leukotriene fractions. When Samples were pooled, 
concentrated, and then analysed with HPLC system, the 
leukotriene fraction showed the peak which appeared in the 
area where the peak of arachidonic acid appeared.
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Fig. 30: HPLC analysis of standard mixture of eicosanoids.
Standard mixture containing unlabeled LTD4 (100 pmole) plus
^H-PGEl (0.1 ixci) f ^H-LTD4 (0.05 nCi) , and ^H-AA (0.15 nCi) 
was analysed through HPLC. HPLC was carried out on a 4.6 x 
250 mm silica C18 column, which was attached to a PERKIN- 
ELMER Series 410 LC pump and a FLO-ONE\Beta Series A-lOO 
radioactivity detector. The solvent system was a low 
pressure gradient of solvent A (acetonitrile:methanolzddHzO 
: acetic acid:EDTA= 1280:800:1916:4:2 grams) and methanol 
eluted at the flow rate of 1 ml/min in the following order:
0 min, 100% A; 30 min, 100% A; 31 min, 100% methanol; 51 
min, 100% methanol; 52 min, 100% A; 67 min, 100% A.
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Fig. 31; HPLC analysis of eicosanoids released from human 
THP-1 cells challenged with S.minnesota LPS.
Human THP-1 cells were pretreated/ labeled, and challenged 
as described in the legend of Fig. 17. After counting 100
pi aliquot from each sample and running the EIA assay, all 
the rest of samples were mixed together and analysed through 
HPLC. HPLC system was performed as described in the legend 
of Fig. 30.
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Membrane Phospholipid was not Recovered in Eicosanoid Fractions Released from Activated Human THP-1 Cells
When lipid from the prostaglandin and leukotriene 
fractions was concentrated and subsequently fractionated by 
HPLC, all of the label eluted in the arachidonic acid 
fraction. This suggested that these eicosanoid fractions 
might have contained arachidonate esterified to more complex 
lipid (e.g. phospholipid) and that the arachidonate was 
hydrolyzed from the glycerol during concentration step.
In order to quantify the amount of arachidonate which 
was released from cells as complex phospholipids, THP-1 
cells were labeled with either ^H-arachidonic acid at 0.5 
^iCi/ml or ^̂ P at 5 pCi/ml overnight. Both ^H-AA and ^̂ P 
labeled cells were then challenged with either S. minnesota 
LPS or S. faecalis LTA at 0, 0.1, 1, 10, 100, 1000 ng/ml in 
RPMI medium with 5% FBS. After incubation at 37°C with 5%
CO2 for 2 hours, all samples were removed and then 
centrifuged. A 200 |il aliquot of the supernatant was removed 
from each sample and counted for total label released from 
the cells, and the remaining portion of each sample was 
fractionated on CIS minicolumns. As shown in Fig. 32, both 
Ĥ and ^̂ P was released from cells challenged with S. 
minnesota LPS or S. faecalis LTA. CIS minicolumn separation 
showed different results between Ĥ and ^̂ P labeled cells.
The recovery of ^H-label was similar to the results 
described above, but almost all the ^̂ P- label was recovered
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in the water phase. The lipid which eluted from the C18 
minicolumn in the prostaglandin or leukotriene fractions did 
not appear to contain phospholipid (Fig. 33}.
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Fig. 32: Label released from human THP-1 cells challenged
at various concentrations with either S.minnesota (R595) LPS 
or S.faecalls LTA.
Human THP-1 cells {8.6 x 10̂  cells/ml x 15 ml) were 
pretreated with vitamin D3 (1 pM/ml) and metabolically 
labeled with either ^H-arachidonic acid at 0.5 pCi/ml or
at 5 pCi/ml overnight. The cells were then challenged with 
either S.minnesota LPS or S.faecalis LTA at the 
concentration course of 0, 0.1, 1, 10, 100, 1000 ng/ml in 
RPMI medium with 5% FBS for two hours. One ml samples were 
then collected, centrifuged, and a 200 |il aliquot of each 
supernatant was counted to determine total label released 
from the cells.
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Fig. 33: Eicosanoids released from activated human THP-1
cells challenged with S.minnesota LPS or S.faecalis LTA. 
Human THP-1 cells were pretreated# labeled, and challenged 
as described in the legend of Fig. 32. After the 200 nl 
aliquot was removed from each sample to be counted, the 
remaining portion of each smaple was fractionated on C18 
minicolumns as described in the legend of Fig. 9. Unbound: 
^H-labeled polar products which did not bind to the C18 
minicolumn; PG: prostaglandin family; LT: leukotriene 
family; AA: arachidonic acid family.
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Chapter IV 
DISCUSSION
Development for Rapid Separation of Different Eicosanoids
Many techniques have been used to separate and extract 
different eicosanoids. Classical techniques for extraction 
of prostaglandins or leukotrienes from biological fluids and 
plasma are liquid - liquid or liquid- solid extractions. In 
liquid - liquid extractions, many different organic 
solvents, such as chloroform, diethyl ether or ethyl acetate 
have been used (27) . However, this technique is time- 
consuming because multi-step extractions and large volumes 
of organic solvents may be necessary for an efficient 
extraction. Liquid - solid extractions have employed solid 
adsorbents such as silica or octadecylsilane silica 
materials from which adsorption of a compound from the 
liquid phase onto the adsorbent material and subsequent 
desorption may result in different recoveries depending on 
the type of adsorbent utilized. Silica and CIS (CDS) 
extraction columns (Sep-Paks) are the most common choice. 
Another octadecylsilane silica material available in 
disposable columns of different sizes distributed by J.T 
Baker has also been found to accomplish the extraction of 
prostaglandins and lipoxygenase metabolites of arachidonic 
acid from buffer with good recoveries (27).
Based on previous research results from our laboratory
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(4), the major classes of eicosanoids we were interested in 
were the prostaglandin family, leukotriene family, and 
arachidonic acid. Several groups have described procedures 
to extract prostaglandins or leukotrienes from plasma or 
other biological fluids, however, a technique for 
simultaneous extraction and separation of all 
prostaglandins, leukotrienes, and arachidonic acid has not 
been demonstrated. A major objective of this present study 
was to develop a procedure for the simultaneous extraction 
and separation of the three classes of eicosanoids with 
liquid - solid extraction technique based on the solid 
adsorbents and using organic solvents which have been 
used in HPLC or TLC procedures.
Comparison of Eicosanoid Separation Efficiency of Silicic 
Acid Column Procedure and C18 Minicolumn Procedure
Initial studies for quick separation of different 
eicosanoids were focused on the evaluation of one-step 
column-centrifugation procedures. For our initial 
experiments, small centrifuge columns were developed using 
silicic acid as absorbant, which was expected to have 
markedly different affinities for the prostaglandin family 
and the leukotriene family. It was essential that all of the 
different eicosanoids have high binding affinity in the 
initial solvent. Each of the eicosanoids could then be 
sequentially eluted with different solvents. We tested
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the binding affinity of the eicosanoids in different 
solvents/ and toluene was finally selected as the solvent 
for loading samples on silicic acid columns. For both the 
silicic acid procedure and CIS minicolumn procedure, the 
solvent systems evaluated in this study for sequential 
elution were selected from solvents which have been used in 
thin-layer chromatography (TLC) and HPLC systems. 
Fractionation of the different classes of eicosanoids on 
hydrophobic CIS minicolumns or silicic acid columns is based 
on the difference in polarity of leukotrienes (LT),- 
prostaglandins (PG) , and arachidonic acid (AA.) (polarity :
PG > LT > AA). The silicic acid column procedure required 
more complicated solvent systems than the CIS minicolumn 
procedure, and this procedure was only effective for 
separation of leukotrienes from prostaglandins and 
arachidonic acid, but not for separation of prostaglandins 
and arachidonic acid (Fig. 11) .
Neither the separation or the recovery of this procedure was 
as effective as the CIS minicolumn procedure (Fig. 10, 13) . 
Based on these observations, the CIS minicolumn procedure 
was finally selected for eicosanoid analysis in this study.
LPS and LTA Activate Eicosanoid Metabolism in Human THP-1 
Cell Line
The human monocytic leukemic cell line, THP-1, which 
differentiates toward macrophages in response to phorbol 1 2 - 
myristate 13-acetate (PMA) or vitamin D3, is an established
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model of induced macrophage differentiation (3). After 
differentiation with 1,25-dihydroxyvitamin D3^ previous 
studies showed that THP-1 cells responded to LPS stimulation 
with a greatly enhanced secretion of proinflammatory 
cytokines and mediators including TNF-a and the arachidonic 
acid metabolites, such as prostaglandin E2 (PGE2), 
thromboxane B2, and prostaglandin F2a (PGF2a). This 
increase required the expression of the CD14 antigen, an 
integral component of a high-affinity LPS receptor (20). Our 
results indicated that THP-1 cells responded well to 
activation with LPS from S. minnesota (R595) and S. abortus, 
and to lipoteichoic acid from S. faecalis, S.pyogenes,
B.subtilis, and S.aureus. Activation significantly enhanced 
release, which was concentration-dependent and time 
dependent, of arachidonic acid metabolites.
The rate-limiting enzyme in the arachidonic acid 
cascade is phospholipase A2 (PLA2), which cleaves 
arachidonic acid residues from membrane phospholipids. This 
enzyme was reported to be activated by LPS in macrophages, 
causing it to localize to the plasma membrane and release 
arachidonic acid (20). It has been documented that relative 
potency of LPS varied with the proportion of lipid A in the 
LPS molecule. Previous studies indicated that the ratio of 
lipid A to polysaccharide in LPS has significant influence 
on the cellular mechanisms and subsequent toxic effects of 
endotoxins and the consequence of gram-negative bacterial
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infections. Due to the structural differences between 
S. minnesota LPS (R-LPS) and S. abortus LPS (S-LPS), they 
might have different effects on the activation of 
phospholipase A 2, causing different subsequent 
pathophysiological consequences.
Our results of CIS minicolumn separation showed there 
were some differences of the arachidonic acid metabolites 
released from THP-1 cells challenged with either S. 
minnesota or S. abortus LPS. Both arachidonic acid and 
leukotrienes, which are the 5'-lipoxygenase products, were 
recovered from the mixture of eicosanoids released from THP- 
1 cells which were challenged with S. minnesota LPS, but no 
measurable amount of prostaglandins were found. In contrast, 
only arachidonic acid was recovered from the eicosanoid 
mixture released from THP-1 cells challenged with smooth-LPS 
from S. abortus, suggesting that S. abortus LPS stimulation 
did not activate the 5'-lipoxygenase pathway in the THP-1 
cell line. Label was recovered, however, in the leukotriene 
fraction from THP-1 cells challenged with S. minnesota 
(R595) LPS, indicating that the 5'-lipoxygenase pathway 
was activated in these cells.
Chemically, LTA is different from LPS, but it shares 
some common physical properties with LPS. LTA is localized 
at the outer surface of the cytoplasmic membrane of Gram- 
positive bacteria (11). Both LTA and LPS are anionic, 
amphiphilic polymers, which contain carbohydrate and 
phosphorus, and both have a hydrophobic glycolipid moiety
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and a hydrophilic end. LTA induces some of the same 
biological and immunological responses which are induced by 
LPS, but compared with LPS, LTA is less toxic. There are 
differences in the relative potencies of different LTA 
preparations. In mouse PEC cultures, S. faecalis and S. 
aureus LTA are comparable to LPS, whereas B. subtilis LTA 
is less potent (4). In this study, we used LTA from S. 
faecalisr S.pyogenes^ B.subtilis^ and S.aureus to challenge 
both THP-1 cells and mouse PEC macrophages. Our results 
indicated that THP-1 cells responded well to the stimulation 
from all of these LTA preparations. C18 minicolumn 
separation of the eicosanoid mixture showed compositions 
similar to that released by S. minnesota LPS (R595) 
challenged cells. Both arachidonic acid and leukotrienes 
were recovered from the separation, but no measurable 
prostaglandins were found. These results suggested 
that the pathway of cell activation by these LTA 
preparations was similar to the activation pathway of R595 
LPS. They could activate both phospholipase A2 and 5'- 
lipoxygenase pathways, causing the release of arachidonic 
acid and leukotrienes. No label was recovered in the 
prostaglandin fraction. The key enzymes in prostaglandin 
synthesis are the constitutive cyclooxygenase, prostaglandin 
H synthase-1 (PGHS-l), and the mitogen-induced 
cyclooxygenase (PGHS-2). The C18 minicolumn separation 
results suggest that cyclooxygenase pathway is not activated 
in the human THP-1 cell line. The result that LTA had
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similar effect as LPS on stimulating arachidonic acid 
release in human THP-1 cells is quite interesting since LTA 
is less toxic than LPS, and it has not been implicated in 
pathological conditions.
HPLC system was applied in this study to analyse each 
fraction of prostaglandin, leukotriene, or arachidonic acid, 
which were fractionated on CIS minicolumns. HPLC analysis 
confirmed the CIS minicolumn separation results that 
arachidonic acid was the main product in eicosanoid mixture 
released from THP-1 cells challenged with S. minnesota LPS. 
The HPLC analysis lacked the sensitivity to detect label in 
the prostaglandin and leukotriene fractions. In order to 
increase sensitivity, the leukotriene fractions from several 
samples were pooled, concentrated by evaporation, and then 
analysed by HPLC. All of the label in these pooled samples 
was eluted in the arachidonic acid fraction. Since the 
amount of arachidonic acid in the eicosanoid mixture was 
much higher than the amount of prostaglandins or 
leukotrienes, it was possible that when the mixture was 
fractionated on CIS minicolumn, some arachidonic acid 
might be eluted with the leukotriene fraction, causing the 
recovery of arachidonic acid in leukotriene fraction with 
HPLC analysis. This is unlikely, however, because when the 
label recovered in the leukotriene fraction was applied to a 
fresh column and re-fractionated all of the label was again 
recovered in the leukotriene fraction. The same results were 
obtained when label recovered in the prostaglandin fraction
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was refractionated. Another possible explanation for this 
observation could be that some other products, which were 
eluted in the PG or LT fraction on the column but 
subsequently chromatographied with AA on the HPLC, were 
released from the THP-1 cells during the R595 LPS 
challenge. Since we just used ^H-LTD4, ^H-PGEl, and ^H-AA as 
standards for HPLC analysis and also for C18 minicolumn 
procedure, it is very possible that some other products 
which could be separated from arachidonic acid on the column 
but not on HPLC.
In contrast, EIA assay results showed that both PGE2 
and LTC4 were recovered from the eicosanoid mixture released 
from THP-1 cells challenged with S. minnesota LPS. But 
compared with LTC4, the amount of PGE2 was much less. The 
amount of PG measured by EIA was below the sensitivity of 
the HPLC. EIA assay could measure prostaglandins at the 
concentration as low as 5 pg/ml. A very low amount of PGE2 
in eicosanoid mixture could not be detected with C18 
minicolumn procedure or HPLC assay, but it could be measured 
with EIA assay.
S. minnesota LPS, S. faecalis LTA and PMA Activate 
Eicosanoid Metabolism in Mouse Peritoneal Macrophages
The toxicity of lipopolysaccharide is a problem in the 
practical use of LPS to enhance the immune response. This 
has led to a search for naturally occurring or modified 
forms of LPS which have reduced toxicity but retain immune
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stimulatory activity. Much evidence has suggested that the 
endotoxic properties of LPS are largely determined by the 
lipid A component which interacts with a defined humoral 
factor (LPS binding protein) and the cellular recognition 
molecular receptor, CD14. The toxicity levels of different 
lipid A preparations show marked differences (5). Removal of 
a phosphate group from lipid A results in a marked reduction 
in pyrogenicity and toxicity. Likewise, removal or 
substitution of the normal fatty acids of lipid A causes 
decreased toxicity (4). Although lipid A is considered to be 
responsible for virtually all the biological activities of 
LPS, the polysaccharide moiety determines the elimination 
kinetics, LPS binding specificity with macrophages, and the 
activation of the alternate pathway of the complement 
system. This is at least part of the reason that smooth and 
rough LPS have differential effects on the release of 
chemical mediators.
It has been previously demonstrated that smooth LPS 
from Pasteurella hemolytica caused marked increases in 
plasma PG, TxB2 and serotonin in sheep (7). Emau and Giri 
reported (8 ) that both smooth and rough LPS caused immediate 
increases in plasma arachidonic acid to its maximal levels 
at various times during the infusion, and the rise in plasma 
arachidonic acid metabolites was greater in response to 
smooth than to rough LPS. They also found although both 
smooth and rough LPS produced an early transient rise in 
plasma serotonin, the two LPSs differed in their abilities
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to decrease plasma serotonin and histamine during the later 
part of endotoxemia.
LTA was also reported to stimulate the respiratory 
burst in human blood monocytes (17), but the immunological 
implications of the interaction of LTA with cells for the 
immune response remains unclear. Some previous results 
suggested that LTA would interact with host immune cells 
directly. The hydrophobic component of LTA is less complex 
than lipid A of LPS, and it has been proposed that the 
reason LTA is less toxic is because LTA is closer in 
structure to eukaryotic membrane glycolipids than lipid 
A (34) . It has been suggested that the hydrophobic 
glycolipid region would be the biologically active part in 
LTA for attachment to unidentified receptor(s) on the 
surface of macrophages, such as lipid A in LPS is the 
minimal structure which is responsible for most of the 
biological properties .of LPS (18).
In our laboratory, Rahul Jasuja reported (4) that 
lipoteichoic acid (LTA) from the Gram-positive bacteria S. 
aureus, S. faecalis, B. subtilis, and B. stearothermophilus 
activated eicosanoid release from mouse peritoneal 
macrophages (mouse PEC). The amount of arachidonic acid 
released was comparable to that released by mouse PEC which 
were activated with toxic LPS from S. abortus. B. subtilis 
LTA stimulated arachidonic acid release, but the amount 
released was much less than the other LTA preparations. 
Lipopolysaccharide (LPS) from S. abortus initiated
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eicosanoid release and showed a maximum release at lower 
concentrations than LTA. The total amount of eicosanoids 
released was about the same for LPS and S. aureus and
S. faecalis LTA. Phorbol myristic acetate (PMA) was also 
tested, and the result showed it was another activator for 
arachidonic acid metabolism. It has been known that PMA, 
which is an analog of diacylglycerol, can permeate the cell 
membrane and activate protein kinase C, causing the release 
of arachidonic acid via phospholipase Az (35). This previous 
study did not determine the relative amount of the different 
classes of eicosanoids in the materials released from 
different cell lines.
My study confirmed that S. minnesota LPS (smooth LPS),
S. faecalis LTA, and PMA activated eicosanoid metabolism in 
mouse peritoneal macrophages (mouse PEC). Furthermore, CIS 
minicolumn separation showed that prostaglandins, 
leukotrienes, and arachidonic acid were recovered in the 
eicosanoid mixture released from mouse PEC challenged with 
R595 LPS, LTA, and PMA, indicating that both cyclooxygenase 
and 5'-lipoxygenase pathways were activated in mouse PEC.
Comparison of the Effect of S. minnesota LPS, S. faecalis 
LTA, and PMA on Eicosanoid Metabolism in Human THP-1 cells 
and Mouse Peritoneal Macrophages
There were marked differences in the relative amount of 
different eicosanoids recovered from the mixture released 
from mouse PEC or human THP-1 cells. When both of the cell
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lines were challenged with S. minnesota LPS, S. faecalis 
LTA, and PMA, CIS minicolumn separation of eicosanoid 
mixtures from activated mouse PEC showed label in the 
prostaglandin, leukotriene, and arachidonic acid fractions. 
Only the leukotriene and arachidonic acid fractions were 
recovered from human THP-1 cells. This result is quite 
interesting since the same results were obtained by 
stimulation with LPS, LTA, or even PMA, which is not a 
bacterial amphiphile. The type of eicosanoids released did 
not vary with the type of activation but with the different 
cell lines. The constitutive cyclooxygenase PGHS-1 and 
inducible cyclooxygenase PGHS-2 are responsible for 
prostaglandin synthesis, whereas 5'-lipoxygenase is 
responsible for leukotriene synthesis. It has been reported 
that the mitogen-inducible cyclooxygenase, PGHS-2, could be 
induced upon LPS stimulation in THP-1 monocytes, and is 
generally thought to be the isoform responsible for the 
resultant burst of prostaglandin and thromboxane synthesis 
(24). Recently, Mazzucco and Warr reported (20) that the 
fungal metabolite trichodimerol (BMS-182123), which 
has demonstrated inhibition of LPS-stimulated tumor necrosis 
factor-a (TNF-a) secretion in both human and murine in 
vitro macrophage models, interfered with LPS-induced 
eicosanoid secretion through an inhibition in the induction 
of the inducible cyclooxygenase, PGHS-2, at the level of 
transcription.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
8 0
In this study/ little prostaglandin was released from 
THP-1 cells challenged with LPS, LTA, and PMA. On the other 
hand, the stimulation of the amphiphiles (both LPS and LTA) 
and PMA could activate the cyclooxygenase pathway in mouse 
peritoneal macrophages, resulting in the release of 
prostaglandins. The mechanisms for this preferable 
activation need further studies.
Another comparison of the effect of LPS, LTA, and PMA 
on eicosanoid metabolism in human THP-1 cells and mouse PEC 
shows that LPS, LTA and PMA activate these two cell lines 
with different stimulative potency. Both of the cell lines 
could responded well to LPS (R595), LTA (S. faecalis) , and 
PMA stimulation and released eicosanoids. But R595 LPS 
appeared to have the most potent stimulative effect on THP-1
cells, releasing two times more eicosanoid than PMA. On the
other hand, PMA was the most potent activator for eicosanoid 
metabolism in mouse PEC, and S. faecalis LTA had the least 
effect for this activation.
PMA acts as an analogue for diglyceride. A possible 
explanation for this observation is that PMA has different ,
binding affinity for the protein kinase C in these two cell
lines. DAG is a source for arachidonic acid by the action of 
diglyceride lipase, and it also can activate protein kinase 
C, which plays an important role in leukocyte activation, 
differentiation of monocytes to macrophages, and arachidonic 
acid release (Fig. 34). It has been previously reported that 
PMA could specially activate protein kinase C, causing the
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release of arachidonic acid. Based on our observation, we 
suggest that PMA might have lower binding ability in THP-1 
cells compared with in mouse PEC, resulting in lower protein 
kinase C activation. Another possibility is that in THP-1 
cells, protein kinase C may not be linked with the 
arachidonic acid metabolic pathway as closely as in mouse 
PEC, so that this enzyme has less of an effect on 
arachidonic acid release in THP-1 cells.
The reason that LPS and LTA have different effects on 
eicosanoid release in THP-1 and mouse cells might be related 
to their different receptors on the cells. Several LPS 
receptors have been identified. The 53- to 55-kDa cell 
surface glycoprotein CD14, which is a 
glycophosphatidylinositol anchored protein, has been 
identified as the main LPS receptor on leukocytes, enabling 
them to be stimulated with LPS by binding serum LPS-binding 
protein (LBP)-LPS complexes at low LPS concentrations. This 
process is facilitated by the catalytic activity of the 
serum protein LPS-binding protein (LBP), which accelerates 
the binding of LPS to CD14 (32). CD18 and LDL-scavenger 
receptor are also LPS receptors, but they do not appear to 
be involved in signal transduction. Receptors of LTA 
have not been identified. LTA has not been found to bind 
the CD14 receptor, but it has been pointed out that LTA from 
several Gram-positive bacteria binds a 28 kDa LPS binding 
protein in mouse serum (19). Previous investigations showed 
that the macrophage scavenger receptor (SR), a glycosylated
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trimeric transmembrane protein, binds directly to many Gram- 
positive bacteria, possibly via LTA. SR binding to other 
ligands is dependent upon the spatial characteristics of the 
repeating negative charge of the ligand. Therefore,
Greenberg and Fischer (12) investigated SR recognition of
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LTA species with various charge densities and distributions, 
and they demonstrated that the SR binds directly to many 
Gram-positive bacteria via negative charges and possibly 
also recognizes polyanionic hydrophilic chains of LTAs.
Their data support the role of surface associated LTA as a 
major ligand of Gram-positive bacteria for binding to SR. 
Based on our findings, we suggest that the distribution of 
LPS and LTA receptors on these two cell lines is different. 
Both LPS and LTA receptors which could function in signal 
transductions might be more abundant on THP-1 cells than 
on mouse PEC. This different distribution of the receptors 
could lead to the different stimulative potency of LPS and 
LTA on these two cell lines, causing more eicosanoids 
released from THP-1 cells than from mouse PEC when 
challenged with LPS or LTA. The other possibility that could 
explain our results would be that the LPS and LTA receptor 
on mouse cells might not be linked to the arachidonic acid 
metabolic pathway as closely as in THP-1 cells, so LPS or 
LTA challenging has less effect on activating arachidonic 
acid metabolism in mouse cells than human THP-1 cells.
The Nature of Desensitization by S. minnesota (R595) LPS 
Treatment in Mouse Peritoneal Macrophages
We tested the ability of S. minnesota LPS to 
desensitize mouse peritoneal macrophages, and the data 
presented in our study showed the treatment with R595 LPS 
desensitized the macrophage cultures to subsequent response
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to LPS challenge. Furthermore, we found that the cell 
culture pretreated with R595 LPS had good response to PMA 
challenge, releasing even more eicosanoids than the cells 
without LPS pretreatment.
Rahul Jasuja reported (4) that S. faecalis and S. 
aureus LTA desensitized mouse PEC to LPS challenge, but B. 
subtilis LTA could not. He also found that the 
desensitization was not specific for pretreatment with LTA. 
Mouse PEC pretreated with LPS were desensitized to LPS 
challenge, and cells pretreated with LTA were unresponsive 
to subsequent LTA challenge. But S. faecalis LTA could not 
desensitize the cells to PMA and calcium ionophore A231B7 
challenge. My study confirmed that R595 LPS could 
desensitize mouse PEC to LPS challenge, and the CIS 
minicolumn separation result showed the main classes of 
eicosanoids released from either desensitized or non­
desensitized cells were similar.
Previous studies from our laboratory (4) indicated that 
the desensitization was not the result of less [̂ H]- 
arachidonic acid uptake during the labeling period, or the 
result of a general down-régulâtion of arachidonic acid 
metabolism. Cells pretreated with LTA during the adherence 
period had an enhanced rate of uptake of [^H]-arachidonate 
during the labeling period, and remained responsive to PMA 
challenge, indicating that there was an increase in the 
turnover of arachidonic acid in these stimulated cells, 
resulting in an increase in both uptake and release. There
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are several possible mechanisms which may be responsible for 
the desensitization of cells to LPS challenge, such as 
alterations of amphiphile receptors, the targets of 
signal transduction, or the cellular regulators of the 
signal transduction pathways. The best characterized LPS 
receptor CD14, as described above, can function by 
delivering LPS to the signaling receptor. GDI8 and the LDL- 
scavenger receptor have not been reported to function in 
signal transduction. Previous results suggested that 
blocking these receptors does not desensitize cells to LPS 
challenge, and the desensitization is not the result of a 
down-regulation of any of the known receptors (9). The 
possible explanations for desensitization could be 
that it is the result of changes in cellular elements 
involved in the interaction of the receptor and transduction 
system or some single step in signal transduction pathways. 
Both tyrosine kinase and protein kinase C have been 
implicated in the LPS activation pathway. As shown in Fig. 
34, in the pathway of arachidonic acid release, the steps 
for cells desensitized with LPS could occur at a point 
before protein kinase C activation.
We also found that R595 LPS pretreatment could not 
desensitize mouse PEC to PMA challenge, which was similar to 
Jasuja's (4) observation that S .faecalis LTA could not 
desensitize mouse PEC to PMA challenge. It has been shown 
that the mechanism for PMA activating arachidonic acid 
metabolism is that PMA permeates the cell membrane and
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directly activates protein kinase C, causing arachidonic 
acid release via phospholipase A2. This mechanism could 
explain the result that R595 LPS and S. faecalis LTA 
pretreatment did not desensitize cells to PMA challenge 
since the pretreatment caused desensitization step which 
occurred at a point before protein kinase C activation, so 
the subsequent treatment of PMA still activated protein 
kinase C, causing the release of arachidonic acid. Our 
observation that subsequent PMA challenge of R595 LPS 
pretreated cells caused even more arachidonic acid release 
than untreated cells could be due to the three hours 
pretreatment of R595 LPS. Previous study in our laboratory 
(4) indicated that mouse PEC pretreated with LTA from S. 
pyogenesf S.aureus, and S. faecalis during the adherence 
period had an enhanced rate of uptake of [^H]-arachidonate 
during the labeling period. Based on this observation, the 
explanation for our result is that pretreatment with R595 
LPS enhanced the uptake of [̂ H] arachidonate during the 
labeling period, which would increase the amount of label in 
the lipid pool, so that more arachidonic acid was released 
during subsequent PMA challenge.
It has been suggested that ceramide is an intracellular 
modulator of cell growth and differentiation, and it is also 
an important second messenger in signal transduction in 
cells of myeloid lineage (15). Examination of the structures 
of LPS and ceramide have revealed a strong similarity 
between the molecules. This present study showed that C2-
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ceramide and sphingomyelinase had the effect on activating 
arachidonic acid metabolism in mouse PEC, and 
dihydroceramide, which was used as a negative control, had 
no apparent effect on this activation. R595 LPS could not 
desensitize the cells to subsequent challenge with C2- 
ceramide or PMA. Most recently, Jean Pfau (unpublished data) 
in our laboratory reported that both LPS and ceramide could 
activate arachidonic acid metabolism in human THP-1 cells, 
and prior exposure to ceramide did not desensitize the cells 
to subsequent challenge with either LPS or ceramide, nor 
could LPS desensitize the cells to challenge with ceramide, 
which is very similar to our result in mouse PEC.
Macrophage-endotoxin interaction has many destructive 
pathophysiological consequences, such as endotoxic shock. 
Desensitization of the responding cells by pretreatment with 
bacterial amphiphiles could be an effective method for 
minimizing the harmful effects caused by macrophage- 
endotoxin interaction.
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1. A CIS minicolumn procedure was developed to separate 
different eicosanoid mixtures into prostaglandin 
fraction, leukotriene fraction, and arachidonic acid 
fraction.
2. The relative amount of label in the different 
eicosanoid fractions released from LPS activated THP-1 
cells was similar throughout the activation period. 
THP-1 macrophages activated with LPS from S. minnesota 
(R595) released both PGEz and LTC4 .
3. The kinetics of activation of THP-1 cells with 
lipoteichoic acid were similar to the kinetics of cells 
activated with LPS. The relative amount of label 
recovered in different eicosanoid fractions was similar 
for THP-1 cells activated with different LTA 
preparations.
4. Pretreatment of THP-1 cells with human gamma interferon 
did not alter the pattern of arachidonic acid 
metabolism.
5- Mouse peritoneal macrophages (PEC) were more sensitive 
to PMA than human THP-1 macrophages.
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6 . R595 LPS pretreatment desensitized mouse peritoneal 
macrophages to subsequent challenge with R595 LPS, but 
this treatment could not desensitize the macrophage 
cultures to subsequent challenge with either C2- 
ceramide or PMA.
7. The composition of the eicosanoid mixture released from 
PMA treated THP-1 cells was similar to LPS and LTA 
treated cells.
8 . Mouse PEC cultures released more label in the 
prostaglandin fraction than human THP-1 cells.
9. HPLC analysis comfirmed the CIS minicolumn separation 
results that arachidonic acid was the main product 
released from THP-1 cells challenged with S. minnesota 
LPS, and no measurable amount of prostaglandin was 
recovered. HPLC result also suggested that some 
product other than prostaglandins or leukotrienes was 
released from THP-1 cells during this challenging.
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